1995
DOI: 10.1378/chest.108.4_supplement.352s
|View full text |Cite
|
Sign up to set email alerts
|

Antithrombotic Therapy in Atrial Fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
113
0
8

Year Published

1998
1998
2007
2007

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 218 publications
(122 citation statements)
references
References 47 publications
1
113
0
8
Order By: Relevance
“…All patients qualified for the study received a standard preventive thromboembolic therapy [11]. Anticoagulant treatment with dose-adjusted acenocumarol was initiated at least 4 weeks before CV and was continued in all patients until normal SR was present for at least 4 weeks.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…All patients qualified for the study received a standard preventive thromboembolic therapy [11]. Anticoagulant treatment with dose-adjusted acenocumarol was initiated at least 4 weeks before CV and was continued in all patients until normal SR was present for at least 4 weeks.…”
Section: Methodsmentioning
confidence: 99%
“…Patients without any proven clinical or echocardiographic factors of systemic embolization or history of previous ischemic events received aspirin (or ticlopidine) as a further therapy. Patients <55 years of age maintaining SR received no pharmacological treatment [11]. Where anticoagulants were discontinued and AF relapsed later than 4 weeks after CV, it was repeated without preceding anticoagulation, but limited only to patients who clearly felt that the recurrence of arrhythmia lasted less than 24 h. Others were given acenocumarol for at least 4 weeks.…”
Section: Methodsmentioning
confidence: 99%
“…Die Stroke-Prevention-Atrial-Fibrillation-(SPAF-)Untersucher werteten die Daten der SPAF-Iund -II-Patienten mit einer Nachbeobachtungszeit von 2,3 Jahre aus [49]. Ein Expertengremium erstellte in Kenntnis der beiden anderen Schemata die dritte Klassifikation [38] (Tabelle 1). Die drei Schemata unterscheiden sich geringfügig, aber dennoch in wesentlichen Punkten, die auch für die Therapie wichtig sind, z.B.…”
Section: Risikostratifikation Für Thromboembolische Ereignisseunclassified
“…Der medizinische Nutzen der Antikoagulation zur Reduzierung des Schlaganfalls ist durch eine Vielzahl von Studien bewiesen, und sie gehört zum Standard der Therapie des persistierenden und permanenten Vorhofflimmerns [35,58]. Auch in der Altersgruppe der Patienten > 75 Jahre ist die Antikoagulation hochgradig kosteneffektiv [60].…”
Section: Figureunclassified